Moreover, loss of NF1 expression has been observed in lung adenocarcinomas and melanomas that are resistant to treatment with EGFR [38] and BRAF [28, 29, 36, 37] inhibitors, respectively. This evidence concerns the gene EGFR and lung adenocarcinoma.